{"protocolSection":{"identificationModule":{"nctId":"NCT02364999","orgStudyIdInfo":{"id":"B7391003"},"secondaryIdInfos":[{"id":"2014-003878-16","type":"EUDRACT_NUMBER"},{"id":"B7391003","type":"OTHER","domain":"Alias Study Number"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER."},"statusModule":{"statusVerifiedDate":"2019-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-05","type":"ACTUAL"},"completionDateStruct":{"date":"2017-12","type":"ACTUAL"},"studyFirstSubmitDate":"2015-02-10","studyFirstSubmitQcDate":"2015-02-10","studyFirstPostDateStruct":{"date":"2015-02-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-05-07","resultsFirstSubmitQcDate":"2018-05-31","resultsFirstPostDateStruct":{"date":"2018-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-01-18","lastUpdatePostDateStruct":{"date":"2019-02-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":719,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Bevacizumab-Pfizer","type":"EXPERIMENTAL","description":"Bevacizumab-Pfizer plus paclitaxel and carboplatin","interventionNames":["Drug: Bevacizumab-Pfizer","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Bevacizumab-EU","type":"ACTIVE_COMPARATOR","description":"Bevacizumab-EU plus paclitaxel and carboplatin","interventionNames":["Drug: Bevacizumab-EU","Drug: Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Bevacizumab-Pfizer","description":"Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.","armGroupLabels":["Bevacizumab-Pfizer"]},{"type":"DRUG","name":"Bevacizumab-EU","description":"bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.","armGroupLabels":["Bevacizumab-EU"]},{"type":"DRUG","name":"Paclitaxel","description":"Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.","armGroupLabels":["Bevacizumab-EU","Bevacizumab-Pfizer"]},{"type":"DRUG","name":"Carboplatin","description":"carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.","armGroupLabels":["Bevacizumab-EU","Bevacizumab-Pfizer"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR) by Week 19","description":"ORR refers to percentage of participants who achieved complete response (CR) or partial response (PR) by Week 19 of the study in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 which was subsequently confirmed by Week 25. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-PD (progressive disease), indeterminate or missing, and no new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes must decrease to normal size); PR: \\>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be normal in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.","timeFrame":"25 weeks"}],"secondaryOutcomes":[{"measure":"Number of Participants With Treatment-Emergent Adverse Events","description":"AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.","timeFrame":"55 weeks"},{"measure":"Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)","description":"Laboratory evaluation included hematology (hemoglobin, white blood cells, platelets and absolute neutrophil count), blood chemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, serum or plasma creatinine, sodium, potassium, total calcium, magnesium, blood urea nitrogen or urea, and albumin ), coagulation (international normalized ratio for prothrombin time and activated partial thromboplastin time) and urinalysis (dipstick followed by a quantitative urine protein analysis for results of 2+ or greater).","timeFrame":"55 weeks"},{"measure":"Duration of Response (DOR)","description":"DOR was defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. DOR was based on the Brookmeyer and Crowley method.","timeFrame":"55 weeks"},{"measure":"Progression Free Survival Rate at 55 Weeks","description":"This outcome measure refers to the possibility of being progression free at 55 weeks since start of study treatment, estimated from the Kaplan-Meier curve using the product-limit method.","timeFrame":"55 weeks"},{"measure":"Survival Rate at 55 Weeks","description":"This outcome measure refers to the possibility of being alive at 55 weeks since start of study treatment, estimated from the Kaplan-Meier curve using the product-limit method.","timeFrame":"55 weeks"},{"measure":"Serum Concentration of Bevacizumab up to 1 Year","timeFrame":"Pre-dose from Cycle 1 to Cycle 17, 2.5 hours post-dose in Cycle 1, and 1.5 hours post-dose in Cycle 5"},{"measure":"Number of Participants With Anti-Drug Antibody (ADA)","description":"ADA assay was performed using a sensitive, specific, and semi-quantitative electrochemiluminescent (ECL) method, which used biotinylated- and ruthenium-labeled PF-06439535 as reagents. Samples with ADA titer greater than or equal to (\\>=) 2.29 were considered positive.","timeFrame":"55 weeks"},{"measure":"Number of Participants With Neutralizing Antibody (NAb)","description":"Only samples that were confirmed positive for ADA were further tested for NAb. The NAb analysis was conducted using a single validated quasi-quantitative enzyme-linked immunosorbent assay (ELISA) that utilized PF-06439535 as a reagent. Samples with NAb titer \\>=1.70 were considered positive.","timeFrame":"55 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients age at least 18 years of age, or age of consent in the region.\n* Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised International System for Staging Lung Cancer criteria of 2010) or recurrent non-small cell lung cancer (NSCLC).\n* Histologically or cytologically confirmed diagnosis of predominately non-squamous NSCLC.\n* Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin based on local standard of care, for the treatment of advanced or metastatic non-squamous NSCLC.\n\nExclusion Criteria:\n\n* Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature.\n* Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that is likely to bleed.\n* Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK translocation positive mutations.\n* Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed if surgical resection for primary disease was performed.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Southern Cancer Center, PC","city":"Daphne","state":"Alabama","zip":"36526","country":"United States","geoPoint":{"lat":30.60353,"lon":-87.9036}},{"facility":"Southern Cancer Center, PC","city":"Mobile","state":"Alabama","zip":"36607","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Southern Cancer Center, PC","city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Beaver Medical Group, L.P.","city":"Highland","state":"California","zip":"92346","country":"United States","geoPoint":{"lat":34.12834,"lon":-117.20865}},{"facility":"Cancer Center of Central Connecticut","city":"New Britain","state":"Connecticut","zip":"06052","country":"United States","geoPoint":{"lat":41.66121,"lon":-72.77954}},{"facility":"Cancer Center of Central Connecticut","city":"Southington","state":"Connecticut","zip":"06489","country":"United States","geoPoint":{"lat":41.59649,"lon":-72.8776}},{"facility":"Phoebe Putney Memorial Hospital","city":"Albany","state":"Georgia","zip":"31701","country":"United States","geoPoint":{"lat":31.57851,"lon":-84.15574}},{"facility":"Swedish Covenant Hospital","city":"Chicago","state":"Illinois","zip":"60625","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Meritus Center for Clinical Research","city":"Hagerstown","state":"Maryland","zip":"21742","country":"United States","geoPoint":{"lat":39.64176,"lon":-77.71999}},{"facility":"Holy Cross Hospital Resource Center","city":"Silver Spring","state":"Maryland","zip":"20902","country":"United States","geoPoint":{"lat":38.99067,"lon":-77.02609}},{"facility":"Maryland Oncology & Hematology, PA","city":"Silver Spring","state":"Maryland","zip":"20904","country":"United States","geoPoint":{"lat":38.99067,"lon":-77.02609}},{"facility":"Holy Cross Hospital, Hospital Pharmacy","city":"Silver Spring","state":"Maryland","zip":"20910","country":"United States","geoPoint":{"lat":38.99067,"lon":-77.02609}},{"facility":"Holy Cross Hospital","city":"Silver Spring","state":"Maryland","zip":"20910","country":"United States","geoPoint":{"lat":38.99067,"lon":-77.02609}},{"facility":"Maryland Oncology & Hematology, PA","city":"Wheaton","state":"Maryland","zip":"20902","country":"United States","geoPoint":{"lat":39.03983,"lon":-77.05526}},{"facility":"St. Joseph's Regional Medical Center","city":"Paterson","state":"New Jersey","zip":"07503","country":"United States","geoPoint":{"lat":40.91677,"lon":-74.17181}},{"facility":"Millennium Oncology","city":"Houston","state":"Texas","zip":"77090","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Millennium Oncology","city":"Kingwood","state":"Texas","zip":"77339","country":"United States","geoPoint":{"lat":30.05691,"lon":-95.18349}},{"facility":"Millennium Oncology","city":"Shenandoah","state":"Texas","zip":"77384","country":"United States","geoPoint":{"lat":30.18022,"lon":-95.45577}},{"facility":"Millennium Oncology","city":"The Woodlands","state":"Texas","zip":"77380","country":"United States","geoPoint":{"lat":30.15799,"lon":-95.48938}},{"facility":"Epic Pharmacy","city":"Lismore","state":"New South Wales","zip":"2480","country":"Australia","geoPoint":{"lat":-28.81354,"lon":153.2773}},{"facility":"The Tweed Hospital","city":"Tweed Heads","state":"New South Wales","zip":"2485","country":"Australia","geoPoint":{"lat":-28.17671,"lon":153.5452}},{"facility":"Cardiac Services, John Flynn Private Hospital -","city":"Tugun","state":"Queensland","zip":"4224","country":"Australia","geoPoint":{"lat":-28.15,"lon":153.5}},{"facility":"South Coast Radiology, John Flynn Private Hospital","city":"Tugun","state":"Queensland","zip":"4224","country":"Australia","geoPoint":{"lat":-28.15,"lon":153.5}},{"facility":"Austin Health - Olivia Newton - John Cancer & Wellness Centre","city":"Heidelberg","state":"Victoria","zip":"3084","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}},{"facility":"Western Health, Sunshine Hospital","city":"St Albans","state":"Victoria","zip":"3021","country":"Australia","geoPoint":{"lat":-37.74496,"lon":144.80049}},{"facility":"Oncoclinic (Clinica de Oncologia e Atendimento de Urgencia Ltda)","city":"Fortaleza","state":"Ceará","zip":"60160230","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Hospital Santa Izabel / Santa Casa de Misericordia da Bahia","city":"Salvador","state":"Estado de Bahia","zip":"40050-410","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"COT - Centro Oncologico do Triangulo Ltda","city":"Uberlândia","state":"Minas Gerais","zip":"38408-150","country":"Brazil","geoPoint":{"lat":-18.91861,"lon":-48.27722}},{"facility":"Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner","city":"Curitiba","state":"Paraná","zip":"81520-060","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"Hospital Bruno Born (Sociedade Beneficencia e Caridade de Lajeado)","city":"Lajeado","state":"Rio Grande do Sul","zip":"95900-000","country":"Brazil","geoPoint":{"lat":-29.46694,"lon":-51.96139}},{"facility":"Oncosinos (Lessa Ferreira Servicos Oncologicos Ltda)","city":"Novo Hamburgo","state":"Rio Grande do Sul","zip":"93510-250","country":"Brazil","geoPoint":{"lat":-29.67833,"lon":-51.13056}},{"facility":"Hospital da Cidade de Passo Fundo - HCPF","city":"Passo Fundo","state":"Rio Grande do Sul","zip":"99010-260","country":"Brazil","geoPoint":{"lat":-28.26278,"lon":-52.40667}},{"facility":"Irmandade da Santa Casa de Misericordia de Porto Alegre - ISCMPA","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90020-090","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Irmandade da Santa Casa de Misericordia de Porto Alegre - Hospital Santa Rita","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90050-170","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Instituto Joinvillense de Hematologia e Oncologia SS Ltda - Clinica de Hematologia e Oncologia","city":"Joinville","state":"Santa Catarina","zip":"89201-260","country":"Brazil","geoPoint":{"lat":-26.30444,"lon":-48.84556}},{"facility":"Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto -","city":"São José do Rio Preto","state":"São Paulo","zip":"15090-000","country":"Brazil","geoPoint":{"lat":-20.81972,"lon":-49.37944}},{"facility":"Instituto de Oncologia de Sorocaba - ONCO Clinicas Especializadas SC Ltda","city":"Sorocaba","state":"São Paulo","zip":"18035-300","country":"Brazil","geoPoint":{"lat":-23.50167,"lon":-47.45806}},{"facility":"Instituto COI de Pesquisa, Educacao e Gestao - COI Clinicas Barra Da Tijuca","city":"Rio de Janeiro","zip":"22793-080","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"lnstituto do Cancer do Estado de Sao Paulo - Octavio Frias de -","city":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Instituto de Assistencia Medica ao Servidor Publico Estadual - IAMSPE/HSPE-FMO","city":"São Paulo","zip":"04039-004","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Complex Oncological Center Shumen EOOD","city":"Shumen","zip":"9700","country":"Bulgaria","geoPoint":{"lat":43.27064,"lon":26.92286}},{"facility":"Instituto Clinico Oncologico del Sur (ICOS)","city":"Temuco","state":"Región de la Araucanía","zip":"4810469","country":"Chile","geoPoint":{"lat":-38.73628,"lon":-72.59738}},{"facility":"Instituto Clínico Oncológico del Sur (ICOS)","city":"Temuco","state":"Región de la Araucanía","zip":"4810469","country":"Chile","geoPoint":{"lat":-38.73628,"lon":-72.59738}},{"facility":"Centro de Investigaciones Clinicas Vina del Mar Ltda.","city":"Viña del Mar","state":"Región de Valparaíso","zip":"2540364","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Bradford Hill Centro de Investigaciones Clinicas","city":"Santiago","state":"Santiago Metropolitan","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Centro Internacional de Estudios Clinicos (CIEC)","city":"Santiago","state":"Santiago Metropolitan","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Fresenius Kabi Chile, Therapia i.v.","city":"Santiago","state":"Santiago Metropolitan","zip":"8940575","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"University Hospital Centre \"Sestre Milosrdnice\"","city":"Zagreb","zip":"10000","country":"Croatia","geoPoint":{"lat":45.81444,"lon":15.97798}},{"facility":"Nemocnice na Plesi s.r.o","city":"Nová Ves pod Pleší","zip":"262 04","country":"Czechia","geoPoint":{"lat":49.83176,"lon":14.27523}},{"facility":"Nemocnice Novy Jicin a.s","city":"Nový Jičín","zip":"741 01","country":"Czechia","geoPoint":{"lat":49.59438,"lon":18.01028}},{"facility":"Lekarna Agel Novy Jicin","city":"Nový Jičín","zip":"74101","country":"Czechia","geoPoint":{"lat":49.59438,"lon":18.01028}},{"facility":"Nemocnice Pelhrimov p.o, Radioterapeuticke oddeleni","city":"Pelhřimov","zip":"39338","country":"Czechia","geoPoint":{"lat":49.43134,"lon":15.22336}},{"facility":"Lekarna Oblastni nemocnice Pribram","city":"Příbram","zip":"26126","country":"Czechia","geoPoint":{"lat":49.68988,"lon":14.01043}},{"facility":"Centre Hospitalier General De Mont De Marsan","city":"Mont-de-Marsan","zip":"40024","country":"France","geoPoint":{"lat":43.89022,"lon":-0.49713}},{"facility":"Centre Hospitalier Montbeliard","city":"Montbéliard","zip":"25200","country":"France","geoPoint":{"lat":47.50957,"lon":6.79823}},{"facility":"L'hopital prive du Confluent S.A.S.","city":"Nantes","zip":"44277","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Hopital d'instruction des armees Sainte Anne","city":"Toulon","zip":"83800","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Klinikum Bayreuth GmbH","city":"Bayreuth","zip":"95445","country":"Germany","geoPoint":{"lat":49.94782,"lon":11.57893}},{"facility":"Evangelische Lungenklinik Berlin","city":"Berlin","zip":"13125","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Viereck-Apotheke","city":"Berlin","zip":"13125","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Vivantes GmbH Apotheke des Humboldt-Klinikums","city":"Berlin","zip":"13509","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Vivantes Klinikum Spandau","city":"Berlin","zip":"13585","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Staedtisches Klinikum Braunschweig gGmbH Apotheke","city":"Braunschweig","zip":"38114","country":"Germany","geoPoint":{"lat":52.26594,"lon":10.52673}},{"facility":"Staedtisches Klinikum Braunschweig gGmbH Institut fuer Roentgendiagnostik und Nuklearmedizin","city":"Braunschweig","zip":"38114","country":"Germany","geoPoint":{"lat":52.26594,"lon":10.52673}},{"facility":"Staedtisches Klinikum Braunschweig gGmbH","city":"Braunschweig","zip":"38114","country":"Germany","geoPoint":{"lat":52.26594,"lon":10.52673}},{"facility":"Fachkrankenhaus Coswig GmbH","city":"Coswig","zip":"01640","country":"Germany","geoPoint":{"lat":51.13204,"lon":13.58312}},{"facility":"Apotheke Johannstadt Sven Ullrich e.K.","city":"Dresden","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Klinikum Esslingen GmbH","city":"Esslingen a.N.","zip":"73730","country":"Germany"},{"facility":"Radiologie Nuklearmedizin Adickesallee","city":"Frankfurt am Main","zip":"60322","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"St. Elisabethen - Krankenhaus","city":"Frankfurt am Main","zip":"60487","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Sued-Apotheke","city":"Frankfurt am Main","zip":"60596","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Asklepios Fachkliniken Muenchen Gauting","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Johannes-Apotheke","city":"Gröbenzell","zip":"82194","country":"Germany","geoPoint":{"lat":48.2,"lon":11.36667}},{"facility":"Krankenhaus Martha-Maria Halle-Doelau gGmbH - Apotheke","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Krankenhaus Martha-Maria Halle-Doelau gGmbH - Institut fuer Radiologie","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Krankenhaus Martha-Maria Halle-Doelau gGmbH","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Zytoservice Deutschland GmbH","city":"Hamburg","zip":"22045","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Katholisches Marienkrankenhaus gGmbH","city":"Hamburg","zip":"22087","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Institut fuer Diagnostische und Interventionelle Radiologie","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Medizinische Hochschule Hannover Zentralapotheke","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Medizinische Hochschule Hannover","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Universitaetsklinikum des Saarlandes - Klinik fuer Diagnostische und Interventionelle Radiologie","city":"Homburg/Saar","zip":"66421","country":"Germany"},{"facility":"Universitaetsklinikum des Saarlandes - Klinik fuer Innere Medizin V - Pneumologie, Allergologie,","city":"Homburg/Saar","zip":"66421","country":"Germany"},{"facility":"Universitaetsklinikum des Saarlandes, Apotheke","city":"Homburg/Saar","zip":"66421","country":"Germany"},{"facility":"Vincentius-Diakonissen-Kliniken gAG Karlsruhe","city":"Karlsruhe","zip":"76137","country":"Germany","geoPoint":{"lat":49.00937,"lon":8.40444}},{"facility":"Vincentius-Diakonissen-Kliniken gAG Klinik fuer Diagnostische und Interventionelle Radiologie","city":"Karlsruhe","zip":"76137","country":"Germany","geoPoint":{"lat":49.00937,"lon":8.40444}},{"facility":"Vincentius-Diakonissen-Kliniken gAG Zentralapotheke","city":"Karlsruhe","zip":"76137","country":"Germany","geoPoint":{"lat":49.00937,"lon":8.40444}},{"facility":"Institut Fuer Versorgungsforschung In Der Onkologie","city":"Koblenz","zip":"56068","country":"Germany","geoPoint":{"lat":50.35357,"lon":7.57883}},{"facility":"Radiologisches Institut Koblenz","city":"Koblenz","zip":"56068","country":"Germany","geoPoint":{"lat":50.35357,"lon":7.57883}},{"facility":"Sonnenschein Apotheke","city":"Koblenz","zip":"56068","country":"Germany","geoPoint":{"lat":50.35357,"lon":7.57883}},{"facility":"Hirsch-Apotheke","city":"Leer","zip":"26789","country":"Germany","geoPoint":{"lat":53.23157,"lon":7.461}},{"facility":"Onkologie UnterEms","city":"Leer","zip":"26789","country":"Germany","geoPoint":{"lat":53.23157,"lon":7.461}},{"facility":"Zentrum fuer Radiologie und Nuklearmedizin am Johannisplatz (ZRN Leipzig)","city":"Leipzig","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Arkana Apotheke OHG","city":"Leipzig","zip":"04315","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"POIS Leipzig GbR, Pneumologisch/onkologisch/internistisches Studienzentrum","city":"Leipzig","zip":"04357","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Onkologie Moers GbR","city":"Moers","zip":"47441","country":"Germany","geoPoint":{"lat":51.45342,"lon":6.6326}},{"facility":"Friedrich-Ebert-Krankenhaus Neumuenster","city":"Neumünster","zip":"24534","country":"Germany","geoPoint":{"lat":54.07399,"lon":9.98456}},{"facility":"University Hospital of Heraklion","city":"Heraklion","state":"Crete","zip":"71110","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"facility":"Univ. of Athens Hosp. of Chest Diseases of Athens ''Sotiria''","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"General Oncology Hospital of Kifissia \"Ag. Anargiroi\"","city":"Athens","zip":"14564","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"University General Hospital Of Patras","city":"Pátrai","zip":"26504","country":"Greece","geoPoint":{"lat":38.2462,"lon":21.73508}},{"facility":"Euromedica General Clinic of Thessaloniki","city":"Thessaloniki","zip":"54645","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"European Inter-Balkan Medical Centre","city":"Thessaloniki","zip":"57001","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Thermi Clinic S.A","city":"Thessaloniki","zip":"57001","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Gen.Hospital \"G. Papanikolaou\"","city":"Thessaloniki","zip":"57010","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Semmelweis Egyetem Klinikai Pulmonologiai Klinikai Gyogyszertar","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Semmelweis Egyetem, Pulmonologiai Klinika","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Csongrad Megyei Mellkasi Betegsegek Szakkorhaza","city":"Deszk","zip":"6772","country":"Hungary","geoPoint":{"lat":46.21802,"lon":20.24322}},{"facility":"Veszprem Megyei Tudogyogyintezet","city":"Farkasgyepű","zip":"8582","country":"Hungary","geoPoint":{"lat":47.2,"lon":17.63333}},{"facility":"Petz Aladar Megyei Oktato Korhaz, Pulmonologiai Osztaly","city":"Győr","zip":"9023","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"Matrai Gyogyintezet Pulmonologiai Osztaly","city":"Mátraháza","zip":"3233","country":"Hungary","geoPoint":{"lat":47.87124,"lon":19.97981}},{"facility":"Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet, Megyei Onkologiai Kozpont","city":"Szolnok","zip":"5000","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"Tudogyogyintezet Torokbalint","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Zala Megyei Korhaz","city":"Zalaegerszeg","zip":"8900","country":"Hungary","geoPoint":{"lat":46.83695,"lon":16.84401}},{"facility":"Mahatma Gandhi Cancer Hospital And Research Institute","city":"Visakhapatnam","state":"Andhra Pradesh","zip":"530 017","country":"India","geoPoint":{"lat":17.68009,"lon":83.20161}},{"facility":"HealthCare Global Enterprises Limited","city":"Bangalore","state":"Karnataka","zip":"560027","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Shatabdi Super Speciality Hospital","city":"Nashik","state":"Maharashtra","zip":"422005","country":"India","geoPoint":{"lat":19.99727,"lon":73.79096}},{"facility":"Sahyadri Clinical Research and Development Center (A Unit of Sahayadri hospitals Limited)","city":"Pune","state":"Maharashtra","zip":"411004","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Sahyadri Speciality Hospital","city":"Pune","state":"Maharashtra","zip":"411004","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Institute of Respiratory Diseases, SMS Medical College & Hospital","city":"Jaipur","state":"Rajasthan","zip":"302016","country":"India","geoPoint":{"lat":26.91962,"lon":75.78781}},{"facility":"UOC Oncologia","city":"Treviglio","state":"BG","zip":"24047","country":"Italy","geoPoint":{"lat":45.52081,"lon":9.59102}},{"facility":"Oncologia Medica, Fondazione Poliambulanza Instituto Ospedaliero","city":"Brescia","state":"BS","zip":"25124","country":"Italy","geoPoint":{"lat":45.53558,"lon":10.21472}},{"facility":"UO Oncologia Medica","city":"Catania","state":"CT","zip":"95123","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Unita di Oncologia Toracica","city":"Meldola","state":"FC","zip":"47014","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"UOC di Oncologia Medica","city":"Lido di Camaiore","state":"LU","zip":"55041","country":"Italy","geoPoint":{"lat":43.90012,"lon":10.2269}},{"facility":"UOSD Pneumologia Oncologica - Padiglione Flaiani","city":"Roma","state":"RM","zip":"00152","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"S.C. Oncologia Medica-Presidio Ospedaliero Sondrio","city":"Sondrio","state":"SO","zip":"23100","country":"Italy","geoPoint":{"lat":46.16852,"lon":9.87134}},{"facility":"UOC Oncologia Medica","city":"Legnago","state":"VR","zip":"37045","country":"Italy","geoPoint":{"lat":45.19365,"lon":11.30227}},{"facility":"National Hospital Organization Hirosaki National Hospital","city":"Hirosaki","state":"Aomori","zip":"036-8545","country":"Japan","geoPoint":{"lat":40.59306,"lon":140.4725}},{"facility":"National Hospital Organization Asahikawa Medical Center","city":"Asahikawa","state":"Hokkaido","zip":"070-8644","country":"Japan","geoPoint":{"lat":43.77063,"lon":142.36489}},{"facility":"National Hospital Organization Himeji Medical Center","city":"Himeji","state":"Hyōgo","zip":"670-8520","country":"Japan","geoPoint":{"lat":34.81667,"lon":134.7}},{"facility":"National Hospital Organization Mito Medical Center","city":"Higashi-ibaraki-gun","state":"Ibaraki","zip":"311-3193","country":"Japan"},{"facility":"Kanazawa University Hospital","city":"Kanazawa","state":"Ishikawa-ken","zip":"920-8641","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Kanagawa Cardiovascular and Respiratory Center","city":"Yokohama","state":"Kanagawa","zip":"236-0051","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"National Hospital Organization Mie Chuo Medical Center","city":"Tsu","state":"Mie-ken","zip":"514-1101","country":"Japan","geoPoint":{"lat":34.73333,"lon":136.51667}},{"facility":"National Hospital Organization Sendai Medical Center","city":"Sendai","state":"Miyagi","zip":"983-8520","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"National Hospital Organization Tokyo National Hospital","city":"Kiyose","state":"Tokyo","zip":"204-8585","country":"Japan","geoPoint":{"lat":35.77952,"lon":139.53014}},{"facility":"National Hospital Organization Tokyo Medical Center","city":"Meguro-Ku","state":"Tokyo","zip":"152-8902","country":"Japan"},{"facility":"National Hospital Organization Disaster Medical Center","city":"Tachikawa","state":"Tokyo","zip":"190-0014","country":"Japan","geoPoint":{"lat":35.7091,"lon":139.41891}},{"facility":"Saiseikai Fukuoka General Hospital","city":"Fukuoka","zip":"810-0001","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"National Hospital Organization Kochi National Hospital","city":"Kochi","zip":"780-8077","country":"Japan","geoPoint":{"lat":33.55,"lon":133.53333}},{"facility":"Japanese Red Cross Okayama Hospital","city":"Okayama","zip":"700-8607","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"National Hospital Organization Oita Medical Center","city":"Ōita","zip":"870-0263","country":"Japan","geoPoint":{"lat":33.23333,"lon":131.6}},{"facility":"Nilai Medical Centre","city":"Kampung Baharu Nilai","state":"Negeri Sembilan","zip":"71800","country":"Malaysia","geoPoint":{"lat":2.8033,"lon":101.7972}},{"facility":"Mount Miriam Cancer Hospital","city":"Tanjung Bungah","state":"Pulau Pinang","zip":"11200","country":"Malaysia","geoPoint":{"lat":5.46491,"lon":100.28165}},{"facility":"Penang Adventist Hospital","city":"George Town","zip":"10350","country":"Malaysia","geoPoint":{"lat":5.41123,"lon":100.33543}},{"facility":"Klinisch Chemisch en Hematologisch Laboratorium (KCHL)","city":"Arnhem","zip":"6815 AD","country":"Netherlands","geoPoint":{"lat":51.98,"lon":5.91111}},{"facility":"Rijnstate Ziekenhuis","city":"Arnhem","zip":"6815 AD","country":"Netherlands","geoPoint":{"lat":51.98,"lon":5.91111}},{"facility":"Ziekenhuis De Gelderse Vallei","city":"Ede","zip":"6716 RP","country":"Netherlands","geoPoint":{"lat":52.03333,"lon":5.65833}},{"facility":"Elkerliek Ziekenhuis","city":"Helmond","zip":"5707 HA","country":"Netherlands","geoPoint":{"lat":51.48167,"lon":5.66111}},{"facility":"Cebu Doctors' University Hospital","city":"Cebu City","state":"CEBU","zip":"6000","country":"Philippines","geoPoint":{"lat":10.31672,"lon":123.89071}},{"facility":"Davao Doctors Hospital","city":"Davao City","state":"Davao DEL SUR","zip":"8000","country":"Philippines","geoPoint":{"lat":7.07306,"lon":125.61278}},{"facility":"Wojewodzki Szpital Zespolony w Elblagu","city":"Elblag","zip":"82-300","country":"Poland","geoPoint":{"lat":54.1522,"lon":19.40884}},{"facility":"Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Kopernika w Lodzi,","city":"Lodz","zip":"93-513","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc w Olsztynie","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Wielkopolskie Centrum Pulmonologii i Torakochirurgii im.Eugenii i Janusza Zeylandow","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"MRUKMED. Lekarz Beata Madej Mruk i Partner. Sp. p. Oddzial nr 1 w Rzeszowie","city":"Rzeszów","zip":"35-021","country":"Poland","geoPoint":{"lat":50.04132,"lon":21.99901}},{"facility":"Samodzielny Publiczny Wojewodzki Szpital Zespolony w Szczecinie Szpital Wojewodzki w","city":"Szczecin-Zdunowo","zip":"70-891","country":"Poland"},{"facility":"Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu Szpital Obserwacyjno-Zakazny","city":"Torun","zip":"87-100","country":"Poland","geoPoint":{"lat":53.01375,"lon":18.59814}},{"facility":"Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Wojskowy Instytut Medyczny, Klinika Onkologii","city":"Warsaw","zip":"04-141","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Wojewodzki Szpital Chorob Pluc im. dr Alojzego Pawelca","city":"Wodzisław Śląski","zip":"44-300","country":"Poland","geoPoint":{"lat":50.00377,"lon":18.47205}},{"facility":"SPAD Imaging International S.R.L","city":"Craiova","state":"Dolj","zip":"200352","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"SC Cardio-Center SRL","city":"Craiova","state":"Dolj","zip":"200382","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"SC Oncolab SRL, Oncologie","city":"Craiova","state":"JUD DOLJ","zip":"200385","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Spitalul Clinic Judetean de Urgenta Targu Mures, Cardiologie","city":"Târgu Mureş","state":"Mureș County","zip":"540136","country":"Romania","geoPoint":{"lat":46.54245,"lon":24.55747}},{"facility":"Spitalul Clinic Judetean Mures, radiologie si imagistica medicala","city":"Târgu Mureş","state":"Mureș County","zip":"540141","country":"Romania","geoPoint":{"lat":46.54245,"lon":24.55747}},{"facility":"Spitalul Clinic Judetean Mures, sectia Clinica de Oncologie Medicala","city":"Târgu Mureş","state":"Mureș County","zip":"540141","country":"Romania","geoPoint":{"lat":46.54245,"lon":24.55747}},{"facility":"S.C. Oncocenter Oncologie Clinica SRL","city":"Timișoara","state":"Timiș County","zip":"300166","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"Medisprof","city":"Cluj-Napoca","zip":"400058","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Spitalul Clinic Municipal","city":"Cluj-Napoca","zip":"400139","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"SC Hiperdia SA","city":"Cluj-Napoca","zip":"400489","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Spitalul Clinic Judetean de Urgenta \"Sf Apostol Andrei\" Constanta Clinica Oncologie Medicala","city":"Constanța","zip":"900591","country":"Romania","geoPoint":{"lat":44.18073,"lon":28.63432}},{"facility":"Centrul Medical Pozimed, SC Pozitron Medical Investigation SRL","city":"Constanța","zip":"900663","country":"Romania","geoPoint":{"lat":44.18073,"lon":28.63432}},{"facility":"S.C. Centrul de Oncologie Sf. Nectarie S.R.L., Oncologie Medicala","city":"Craiova","zip":"200347","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"SC Radiotherapy Center Cluj SRL","city":"Jud Cluj","zip":"407280","country":"Romania"},{"facility":"Hiperdia Timisoara, Cardiologie","city":"Timișoara","zip":"300158","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"Hiperdia Timisoara, Radiologie si imagistica medicala","city":"Timișoara","zip":"300158","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"Dr's Grineva Private Clinic","city":"Sochi","state":"Krasnodarskiy Kray","zip":"354010","country":"Russia","geoPoint":{"lat":43.59699,"lon":39.72477}},{"facility":"SHI Oncology Dispensary #2 of Health Department of Krasnodar Region","city":"Sochi","state":"Krasnodarskiy Kray","zip":"354057","country":"Russia","geoPoint":{"lat":43.59699,"lon":39.72477}},{"facility":"\"SAHI of Moscow \"\"Moscow City Oncology Hospital #62 of Health Department of Moscow\"\"\"","city":"P/o Stepanovskoe","state":"Moscow Oblast","zip":"143423","country":"Russia"},{"facility":"\"RBHI \"\"Kursk Regional Clinical Oncology Dispensary\"\" of Healthcare Committee of Kursk Region\"","city":"Kislino Steading of Kursk Region","state":"Ryshkovskiy Village Council","zip":"305524","country":"Russia"},{"facility":"Federal State Budgetary Institution of Healthcare \"Clinical Hospital #","city":"Lermontov","state":"Stavropol Kray","zip":"357340","country":"Russia","geoPoint":{"lat":44.1072,"lon":42.97798}},{"facility":"SBHI of Stavropol Region \"Pyatigorsk Oncology Dispensary\"","city":"Pyatigorsk","state":"Stavropol Kray","zip":"357502","country":"Russia","geoPoint":{"lat":44.05,"lon":43.05036}},{"facility":"Stavropol Krai State Budget Healthcare Institute \"Stavropol Regional Oncology Clinic\"","city":"Stavropol","state":"Stavropol Kray","zip":"355047","country":"Russia","geoPoint":{"lat":45.03442,"lon":41.9642}},{"facility":"SBHI of Stavropol Region \"Essentuki Central City Hospital\"","city":"Yessentuki","state":"Stavropol Kray","zip":"357600","country":"Russia","geoPoint":{"lat":44.04826,"lon":42.85638}},{"facility":"S.G. Primushko Republican Clinical Oncology Dispensary","city":"Izhevsk","state":"Udmurt Republic","zip":"426067","country":"Russia","geoPoint":{"lat":56.85225,"lon":53.19862}},{"facility":"SBHI of Vladimir Region \"Regional Clinical Oncology Dispensary\"","city":"Vladimir","state":"Vladimirskaya Oblast’","zip":"600020","country":"Russia","geoPoint":{"lat":56.13854,"lon":40.39976}},{"facility":"State Budget Healthcare Institution of Arkhangelsk Region","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"Evimed Llc","city":"Chelyabinsk","zip":"454048","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"Chelyabinsk Regional Hospital","city":"Chelyabinsk","zip":"454076","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"SBHI \"Chelyabinsk Regional Clinical Hospital\"","city":"Chelyabinsk","zip":"454076","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"\"SBHI \"\"Chelyabinsk Regional Clinical Oncology Dispensary\"\"\"","city":"Chelyabinsk","zip":"454087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"Chelyabinsk Regional Clinical Oncology Dispensary","city":"Chelyabinsk","zip":"454087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"MRT-Expert, LLC","city":"Chelyabinsk","zip":"454087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"Road Clinical Hospital on the station Chelyabinsk of OJSC \"RZD\"","city":"Chelyabinsk","zip":"454092","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"SBHI \"Regional clinical hospital #2\" of MoH of Krasnodar Region","city":"Krasnodar","zip":"350012","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"facility":"FSBI \"N.N.Blokhin Russian Cancer Research Center\" RAMS","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"P.A.Hertsen Moscow Oncology Research Institute - Branch of the National Medical Radiological","city":"Moscow","zip":"125284","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Privolzhskiy District Medical Center of Federal Biomedical Agency","city":"Nizhny Novgorod","zip":"603001","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"SBHI NR Clinical Diagnostic Center","city":"Nizhny Novgorod","zip":"603006","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"SBHI of NNR Nizhniy Novgorod Regional Oncology Dispensary","city":"Nizhny Novgorod","zip":"603081","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"SBHI of NNR Nizhniy Novgorod Regional Oncology Dispensary","city":"Nizhny Novgorod","zip":"603163","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"\"Budgetary Healthcare Institution of Omsk Region \"\"Clinical Oncology Dispensary\"\"\"","city":"Omsk","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"SBEI HPE RyazSMU of MoH of Russia based on SBI of Ryazan Region","city":"Ryazan","zip":"390011","country":"Russia","geoPoint":{"lat":54.62696,"lon":39.70415}},{"facility":"FSBI 'Scientific-Research Oncology Institute n.a. N.N.Petrov' of MoH of RF","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"SPb SBHI \"City Clinical Oncology Dispensary\"","city":"Saint Petersburg","zip":"198255","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Saratov scientific research institute of traumatology and orthopedics","city":"Saratov","zip":"410002","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"NHI Road clinical hospital at the st. Saratov II of OJSC Russian Railways","city":"Saratov","zip":"410004","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"Clinical hospital n.a. S.R. Mirotvortseva of SSMU","city":"Saratov","zip":"410054","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"Limited Liability Company \"Common health\"","city":"Sochi","zip":"354003","country":"Russia","geoPoint":{"lat":43.59699,"lon":39.72477}},{"facility":"The Medical Oncology Centre of Rosebank","city":"Johannesburg","state":"Gauteng","zip":"2196","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Amanzimtoti Oncology Centre","city":"eManzimtoti","state":"KwaZulu-Natal","zip":"4126","country":"South Africa","geoPoint":{"lat":-30.05219,"lon":30.88527}},{"facility":"Drs Schnetler, Corbett and Partners Inc","city":"Cape Town","state":"Western Cape","zip":"7500","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Dr Lior Sareli Inc","city":"Cape Town","state":"Western Cape","zip":"7560","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Cape Town Oncology Trials (Pty) Ltd","city":"Kraaifontein","state":"Western Cape","zip":"7570","country":"South Africa","geoPoint":{"lat":-33.84808,"lon":18.71723}},{"facility":"VHS Medical Center","city":"Seoul","state":"Gangdong-gu","zip":"05368","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam-si","state":"Gyeonggi-do","zip":"13620","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Ajou University Hospital","city":"Suwon","state":"Gyeonggi-do","zip":"16499","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Chungbuk National University Hospital","city":"Cheongju-si","state":"North Chungcheong","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"The Catholic University of Korea, Seoul St.Mary's Hospital","city":"Seoul","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Son Llatzer","city":"Palma de Mallorca","state":"Balearic Islands","zip":"07198","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Corporacio Sanitaria Parc Tauli","city":"Sabadell","state":"Barcelona","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"Hospital Universitario Fundacion Alcorcon","city":"Alcorcón","state":"Madrid","zip":"28922","country":"Spain","geoPoint":{"lat":40.34582,"lon":-3.82487}},{"facility":"Hospital Universitario Fundacion Jimenez Diaz","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital 12 de Octubre","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz, Servicio de Oncologia","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Consorcio Hospital Universitario General De Valencia","city":"Valencia","zip":"46014","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Arnau de Vilanova","city":"Valencia","zip":"46015","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Changhua Christian Hospital","city":"Changhua","zip":"500","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"Chulalongkorn University","city":"Patumwan","state":"Bangkok","zip":"10330","country":"Thailand"},{"facility":"Chiangrai Prachanukroh Hospital","city":"Muang","state":"Changwat Chiang Rai","zip":"57000","country":"Thailand"},{"facility":"Chula Clinical Research Center","city":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Clinical Research Center, Phramongkutklao Hospital","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Medical Oncology Unit, Department of Medicine, Phramongkutklao Hospital","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital,","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Prachachuen Imaging Center Co., Ltd.","city":"Bangkok","zip":"10900","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Oncology Unit, Department of Medicine, Faculty of Medicine, Naresuan University","city":"Phitsanulok","zip":"65000","country":"Thailand","geoPoint":{"lat":16.82481,"lon":100.25858}},{"facility":"Baskent Universitesi Tip Fakultesi Adana Hastanesi","city":"Adana","zip":"01120","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Cukurova Universitesi Tip Fakultesi Balcali Hastanesi","city":"Adana","zip":"01330","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Hacettepe Universitesi Tip Fakultesi","city":"Ankara","zip":"06230","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Diskapi Yildirim Beyazit Egitim ve Arastirma Hastanesi","city":"Ankara","zip":"06330","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Ankara Universitesi Tip Fakultesi Cebeci Hastanesi","city":"Ankara","zip":"06590","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Yildirim Beyazit Universitesi Tip Fakultesi Ataturk Egitim ve Arastirma Hastanesi","city":"Ankara","zip":"06800","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Yedikule Gogus Hastaliklari ve Gogus Cerrahisi","city":"Istanbul","zip":"34020","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi","city":"Istanbul","zip":"34093","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Istanbul Universitesi Onkoloji Enstitusu","city":"Istanbul","zip":"34093","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Iyitem Goruntuleme ve Tani Merkezi","city":"Istanbul","zip":"34096","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari","city":"Istanbul","zip":"34098","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Prof Dr Nuri Tenekeci Tani Merkezi","city":"Istanbul","zip":"34371","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Euromed Goruntuleme ve Tani Merkezi","city":"Istanbul","zip":"34724","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ege Universitesi Tip Fakultesi lc Hastaliklari Anabilim Dali","city":"Izmir","zip":"35040","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"LLC \"Medical clinic \"INNOVACIA\", chemotherapy department","city":"Liutizh","state":"Kyiv Oblast","zip":"07352","country":"Ukraine","geoPoint":{"lat":50.6835,"lon":30.39324}},{"facility":"\"Municipal Institution \"\"Chernivtsi Regional Clinical Oncology Dispensary\"\",","city":"Chernivtsi","zip":"58013","country":"Ukraine","geoPoint":{"lat":48.29045,"lon":25.93241}},{"facility":"MI 'City Dnipropetrovsk Multi-field Clin. Hospital #4 of DRC', Dep.-nt of Chemotherapy;","city":"Dnipropetrovsk","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Communal Non-Profit Enterprise \"Regional Center of Oncology\",","city":"Kharkiv","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"MI 'Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council'","city":"Kryvyi Rih","zip":"50048","country":"Ukraine","geoPoint":{"lat":47.90572,"lon":33.39404}},{"facility":"Lviv State Oncologic Regional Treatment and Diagnostic Center","city":"Lviv","zip":"79031","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Poltava Reg. Clinical Oncology Dispensary of PRC, thoracic department, SHEI of Ukr.","city":"Poltava","zip":"36011","country":"Ukraine","geoPoint":{"lat":49.58925,"lon":34.55367}},{"facility":"\"RMI \"\"Sumy Reg. Clin. Oncology Dispensary\"\". oncothoracic dep.-nt. Surny State Univ.,","city":"Sumy","zip":"40022","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"\"Central City Clinical Hospital, City Oncology Center, SHEI \"\"Uzhhorod National University\"\"","city":"Uzhhorod","zip":"88017","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"Vinnytsia Regional Clinical Oncology Dispensary","city":"Vinnytsia","zip":"21029","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}}]},"referencesModule":{"references":[{"pmid":"31768697","type":"DERIVED","citation":"Li CSW, Sweeney K, Cronenberger C. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(R)) in patients with advanced non-squamous non-small cell lung cancer. Cancer Chemother Pharmacol. 2020 Mar;85(3):487-499. doi: 10.1007/s00280-019-03946-8. Epub 2019 Nov 26."},{"pmid":"31338773","type":"DERIVED","citation":"Reinmuth N, Bryl M, Bondarenko I, Syrigos K, Vladimirov V, Zereu M, Bair AH, Hilton F, Liau K, Kasahara K. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin(R)), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. BioDrugs. 2019 Oct;33(5):555-570. doi: 10.1007/s40259-019-00363-4."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7391003&StudyName=A%20Phase%203%20Randomized%2C%20Double-blind%20Study%20Of%20Pf%2006439535%20Plus%20Paclitaxel-carboplatin%20And%20Bevacizumab%20Plus%20Paclitaxel%20-carboplatin%20For%20The%20First-line%20Treatment%20Of%20Patients%20With%20Advanced%20Non-squamous%20Non-small%20Cell%20Lung%20Cancer."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 719 participants were enrolled in this study, and 5 of them did not receive any therapy. One (1) additional participant received only chemotherapy, and did not receive blinded bevacizumab.","groups":[{"id":"FG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"FG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"358"},{"groupId":"FG001","numSubjects":"361"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"356"},{"groupId":"FG001","numSubjects":"358"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"193"},{"groupId":"FG001","numSubjects":"188"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"165"},{"groupId":"FG001","numSubjects":"173"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"136"},{"groupId":"FG001","numSubjects":"138"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Randomized but did not receive treatment","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Baseline analysis population is the Intent-to-Treat (ITT) population and it included all participants who were randomized to study treatment.","groups":[{"id":"BG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"BG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"358"},{"groupId":"BG001","value":"361"},{"groupId":"BG002","value":"719"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.7","spread":"9.5"},{"groupId":"BG001","value":"60.9","spread":"8.9"},{"groupId":"BG002","value":"61.3","spread":"9.2"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"18-44 years","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}]}]},{"title":"45-64 years","categories":[{"measurements":[{"groupId":"BG000","value":"198"},{"groupId":"BG001","value":"222"},{"groupId":"BG002","value":"420"}]}]},{"title":">= 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"263"}]}]}]},{"title":"Sex/Gender, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Female","categories":[{"measurements":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"252"}]}]},{"title":"Male","categories":[{"measurements":[{"groupId":"BG000","value":"237"},{"groupId":"BG001","value":"230"},{"groupId":"BG002","value":"467"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"WHITE","categories":[{"measurements":[{"groupId":"BG000","value":"319"},{"groupId":"BG001","value":"319"},{"groupId":"BG002","value":"638"}]}]},{"title":"BLACK","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]},{"title":"ASIAN","categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"76"}]}]},{"title":"OTHER","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR) by Week 19","description":"ORR refers to percentage of participants who achieved complete response (CR) or partial response (PR) by Week 19 of the study in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 which was subsequently confirmed by Week 25. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-PD (progressive disease), indeterminate or missing, and no new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes must decrease to normal size); PR: \\>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be normal in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.","populationDescription":"The Intent-to-Treat (ITT) population was used for analysis of ORR, and it included all participants who were randomized to study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"25 weeks","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"358"},{"groupId":"OG001","value":"361"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","lowerLimit":"40.01","upperLimit":"50.57"},{"groupId":"OG001","value":"44.6","lowerLimit":"39.40","upperLimit":"49.89"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Calculated based on 2-sided Miettinen and Nurminen method without strata for risk difference for confirmed response. EU equivalence margins (95% CI in -13% to 13%).","paramType":"Risk Difference (RD)","paramValue":"0.6531","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.6080","ciUpperLimit":"7.9082","estimateComment":"PF-06439535 vs Bevacizumab-EU"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Calculated based on 2-sided Miettinen and Nurminen method without strata for risk ratio for confirmed response. US equivalence margins (90% CI in 0.73 to 1.37).","paramType":"Risk Ratio (RR)","paramValue":"1.0146","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.8856","ciUpperLimit":"1.1625","estimateComment":"PF-06439535 vs Bevacizumab-EU"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Calculated based on 2-sided Miettinen and Nurminen method without strata for risk ratio for confirmed response. Japan equivalence margins (95% CI in 0.729 to 1.371).","paramType":"Risk Ratio (RR)","paramValue":"1.0146","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.8628","ciUpperLimit":"1.1933","estimateComment":"PF-06439535 vs Bevacizumab-EU"}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events","description":"AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.","populationDescription":"The analysis population included all participants who were randomized and received at least 1 dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"55 weeks","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"358"}]}],"classes":[{"title":"All-causality AE","categories":[{"measurements":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"347"}]}]},{"title":"All-causality SAE","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"80"}]}]},{"title":"Bevacizumab-related AE","categories":[{"measurements":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"199"}]}]},{"title":"Bevacizumab-related SAE","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"17"}]}]},{"title":"Grade 1 all-causality AE","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"41"}]}]},{"title":"Grade 2 all-causality AE","categories":[{"measurements":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"134"}]}]},{"title":"Grade 3 all-causality AE","categories":[{"measurements":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"104"}]}]},{"title":"Grade 4 all-causality AE","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"44"}]}]},{"title":"Grade 5 all-causality AE","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"24"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)","description":"Laboratory evaluation included hematology (hemoglobin, white blood cells, platelets and absolute neutrophil count), blood chemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, serum or plasma creatinine, sodium, potassium, total calcium, magnesium, blood urea nitrogen or urea, and albumin ), coagulation (international normalized ratio for prothrombin time and activated partial thromboplastin time) and urinalysis (dipstick followed by a quantitative urine protein analysis for results of 2+ or greater).","populationDescription":"The analysis population included all participants who were randomized and received at least 1 dose of study treatment, and had laboratory evaluation done.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"55 weeks","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"348"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"304"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR)","description":"DOR was defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. DOR was based on the Brookmeyer and Crowley method.","populationDescription":"The analysis population included participants in ITT population (all participants who were randomized to study treatment) who had a confirmed objective response achieved by Week 19.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"55 weeks","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"161"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","lowerLimit":"31.6","upperLimit":"43.6"},{"groupId":"OG001","value":"28.7","lowerLimit":"27.0","upperLimit":"36.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Hazard ratio of PF-06439535 versus Bevacizumab-EU; a hazard ratio =1 indicated no difference in progressive disease(PD)/death between 2 reporting groups; \\>1 indicated an increase in PD/death in PF-06439535; \\<1 indicated an increase in PD/death in bevacizumab-EU.","pValue":"0.1077","statisticalMethod":"Log Rank","statisticalComment":"Stratified by smoking, sex and region.","paramType":"Hazard Ratio (HR)","paramValue":"0.800","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.608","ciUpperLimit":"1.051"}]},{"type":"SECONDARY","title":"Progression Free Survival Rate at 55 Weeks","description":"This outcome measure refers to the possibility of being progression free at 55 weeks since start of study treatment, estimated from the Kaplan-Meier curve using the product-limit method.","populationDescription":"The ITT population was used for analysis, and it included all participants who were randomized to study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"55 weeks","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"358"},{"groupId":"OG001","value":"361"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","lowerLimit":"26.9","upperLimit":"37.8"},{"groupId":"OG001","value":"30.5","lowerLimit":"25.3","upperLimit":"35.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Hazard ratio of PF-06439535 versus Bevacizumab-EU; a hazard ratio =1 indicated no difference in progressive disease(PD)/death between 2 reporting groups; \\>1 indicated an increase in PD/death in PF-06439535; \\<1 indicated an increase in PD/death in bevacizumab-EU.","pValue":"0.4492","statisticalMethod":"Log Rank","statisticalComment":"Stratified by smoking, sex and region.","paramType":"Hazard Ratio (HR)","paramValue":"0.931","ciPctValue":"95","ciLowerLimit":"0.777","ciUpperLimit":"1.116"}]},{"type":"SECONDARY","title":"Survival Rate at 55 Weeks","description":"This outcome measure refers to the possibility of being alive at 55 weeks since start of study treatment, estimated from the Kaplan-Meier curve using the product-limit method.","populationDescription":"The ITT population was used for analysis, and it included all participants who were randomized to study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"55 weeks","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"358"},{"groupId":"OG001","value":"361"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.8","lowerLimit":"60.5","upperLimit":"70.6"},{"groupId":"OG001","value":"64.1","lowerLimit":"58.6","upperLimit":"69.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Hazard ratio of PF-06439535 versus Bevacizumab-EU; a hazard ratio =1 indicated no difference in progressive disease(PD)/death between 2 reporting groups; \\>1 indicated an increase in PD/death in PF-06439535; \\<1 indicated an increase in PD/death in bevacizumab-EU.","pValue":"0.4726","statisticalMethod":"Log Rank","statisticalComment":"Stratified by smoking, sex and region.","paramType":"Hazard Ratio (HR)","paramValue":"0.918","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.729","ciUpperLimit":"1.157"}]},{"type":"SECONDARY","title":"Serum Concentration of Bevacizumab up to 1 Year","populationDescription":"The analysis population included all participants in the per-protocol population (all participants who were randomized and received study treatment as planned and had no major protocol deviations) who had at least 1 drug concentration measurement after administration of study treatment.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose from Cycle 1 to Cycle 17, 2.5 hours post-dose in Cycle 1, and 1.5 hours post-dose in Cycle 5","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"354"}]}],"classes":[{"title":"Pre-dose in Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"338"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.08","spread":"705.53"},{"groupId":"OG001","value":"116.4","spread":"1032.1"}]}]},{"title":"2.5 hours post-dose in Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"326"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"280000","spread":"103260"},{"groupId":"OG001","value":"302200","spread":"100360"}]}]},{"title":"Pre-dose in Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"326"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54350","spread":"44479"},{"groupId":"OG001","value":"58930","spread":"49452"}]}]},{"title":"Pre-dose in Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"211"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81090","spread":"48671"},{"groupId":"OG001","value":"83350","spread":"32384"}]}]},{"title":"Pre-dose in Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"299"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100900","spread":"54979"},{"groupId":"OG001","value":"99750","spread":"50531"}]}]},{"title":"Pre-dose in Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"257"},{"groupId":"OG001","value":"271"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"105300","spread":"48469"},{"groupId":"OG001","value":"110000","spread":"65416"}]}]},{"title":"1.5 hours post-dose in Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"201"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"360700","spread":"131170"},{"groupId":"OG001","value":"377200","spread":"142250"}]}]},{"title":"Pre-dose in Cycle 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"268"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"112000","spread":"40825"},{"groupId":"OG001","value":"116700","spread":"53844"}]}]},{"title":"Pre-dose in Cycle 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"117300","spread":"53844"},{"groupId":"OG001","value":"122100","spread":"47793"}]}]},{"title":"Pre-dose in Cycle 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"208"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"123600","spread":"48893"},{"groupId":"OG001","value":"126400","spread":"52985"}]}]},{"title":"Pre-dose in Cycle 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"193"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"127200","spread":"46200"},{"groupId":"OG001","value":"140900","spread":"62548"}]}]},{"title":"Pre-dose in Cycle 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"125700","spread":"50769"},{"groupId":"OG001","value":"135900","spread":"53975"}]}]},{"title":"Pre-dose in Cycle 11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"129500","spread":"61329"},{"groupId":"OG001","value":"135600","spread":"54531"}]}]},{"title":"Pre-dose in Cycle 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"135200","spread":"64560"},{"groupId":"OG001","value":"136300","spread":"51312"}]}]},{"title":"Pre-dose in Cycle 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"130900","spread":"58093"},{"groupId":"OG001","value":"139700","spread":"53750"}]}]},{"title":"Pre-dose in Cycle 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"117"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"128000","spread":"50840"},{"groupId":"OG001","value":"136200","spread":"53439"}]}]},{"title":"Pre-dose in Cycle 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"104"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"134000","spread":"55933"},{"groupId":"OG001","value":"134000","spread":"49663"}]}]},{"title":"Pre-dose in Cycle 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"137000","spread":"54813"},{"groupId":"OG001","value":"128600","spread":"49742"}]}]},{"title":"Pre-dose in Cycle 17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"134800","spread":"86847"},{"groupId":"OG001","value":"127500","spread":"52784"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Drug Antibody (ADA)","description":"ADA assay was performed using a sensitive, specific, and semi-quantitative electrochemiluminescent (ECL) method, which used biotinylated- and ruthenium-labeled PF-06439535 as reagents. Samples with ADA titer greater than or equal to (\\>=) 2.29 were considered positive.","populationDescription":"The analysis population included all participants who were randomized and received at least 1 dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"55 weeks","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"358"}]}],"classes":[{"title":"Cycle 1 pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"Overall (post-treatment)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"350"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Neutralizing Antibody (NAb)","description":"Only samples that were confirmed positive for ADA were further tested for NAb. The NAb analysis was conducted using a single validated quasi-quantitative enzyme-linked immunosorbent assay (ELISA) that utilized PF-06439535 as a reagent. Samples with NAb titer \\>=1.70 were considered positive.","populationDescription":"The analysis population included all participants who had positive ADA results at any time point.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"55 weeks","groups":[{"id":"OG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."},{"id":"OG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]}],"classes":[{"title":"Cycle 1 pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Overall (post-treatment)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"55 weeks","description":"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","eventGroups":[{"id":"EG000","title":"PF-06439535","description":"Participants received up to a maximum of 6 cycles of PF-06439535 (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by PF-06439535 monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin.","deathsNumAffected":144,"deathsNumAtRisk":356,"seriousNumAffected":81,"seriousNumAtRisk":356,"otherNumAffected":328,"otherNumAtRisk":356},{"id":"EG001","title":"Bevacizumab-EU","description":"Participants received up to a maximum of 6 cycles of Bevacizumab-EU (initial dose was 15 mg/kg) plus paclitaxel (initial dose was 200 mg/m\\*2) and carboplatin (initial dose was AUC 6, based on participant's pre-existing renal function and desired platelet nadir), followed by Bevacizumab-EU monotherapy until disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred. All 3 drugs were given by intravenous (IV) infusion on Day 1 in each 21-day cycle and dose reduction was allowed for paclitaxel and carboplatin in response to toxicity. Paclitaxel was administered before carboplatin.","deathsNumAffected":149,"deathsNumAtRisk":358,"seriousNumAffected":80,"seriousNumAtRisk":358,"otherNumAffected":333,"otherNumAtRisk":358},{"id":"EG002","title":"Total","description":"This reporting group include all participants who received at least 1 dose of study treatment from PF-06439535 and Bevacizumab-EU groups.","deathsNumAffected":293,"deathsNumAtRisk":714,"seriousNumAffected":161,"seriousNumAtRisk":714,"otherNumAffected":661,"otherNumAtRisk":714}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":358},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":714}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":356},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":358},{"groupId":"EG002","numEvents":14,"numAffected":12,"numAtRisk":714}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":714}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":356},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":358},{"groupId":"EG002","numEvents":13,"numAffected":10,"numAtRisk":714}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":714}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":356},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":358},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":714}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Cardiovascular insufficiency","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Right ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":714}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Neutropenic colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Peptic ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Small intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":714}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":358},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":714}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":356},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":358},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":714}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":714}]},{"term":"Cholangitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Anal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Disseminated tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":714}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":714}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Oral fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":356},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":358},{"groupId":"EG002","numEvents":17,"numAffected":14,"numAtRisk":714}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":714}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Subarachnoid haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":714}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":714}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Bone cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":714}]},{"term":"Tumour necrosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Haemorrhagic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":358},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":714}]},{"term":"Mononeuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Renal cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":714}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":714}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":714}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":714}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":356},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":358},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":714}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":356},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":358},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":714}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":714}]},{"term":"Brachiocephalic vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Embolism arterial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":714}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Shock haemorrhagic","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":356},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]},{"term":"Subgaleal haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":356},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":358},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":714}]}],"otherEvents":[{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":26,"numAtRisk":356},{"groupId":"EG001","numEvents":56,"numAffected":30,"numAtRisk":358},{"groupId":"EG002","numEvents":100,"numAffected":56,"numAtRisk":714}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":130,"numAffected":59,"numAtRisk":356},{"groupId":"EG001","numEvents":144,"numAffected":66,"numAtRisk":358},{"groupId":"EG002","numEvents":274,"numAffected":125,"numAtRisk":714}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":122,"numAffected":55,"numAtRisk":356},{"groupId":"EG001","numEvents":125,"numAffected":66,"numAtRisk":358},{"groupId":"EG002","numEvents":247,"numAffected":121,"numAtRisk":714}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":39,"numAtRisk":356},{"groupId":"EG001","numEvents":36,"numAffected":27,"numAtRisk":358},{"groupId":"EG002","numEvents":81,"numAffected":66,"numAtRisk":714}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":46,"numAtRisk":356},{"groupId":"EG001","numEvents":66,"numAffected":48,"numAtRisk":358},{"groupId":"EG002","numEvents":125,"numAffected":94,"numAtRisk":714}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":111,"numAffected":71,"numAtRisk":356},{"groupId":"EG001","numEvents":112,"numAffected":69,"numAtRisk":358},{"groupId":"EG002","numEvents":223,"numAffected":140,"numAtRisk":714}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":41,"numAtRisk":356},{"groupId":"EG001","numEvents":42,"numAffected":33,"numAtRisk":358},{"groupId":"EG002","numEvents":94,"numAffected":74,"numAtRisk":714}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":46,"numAtRisk":356},{"groupId":"EG001","numEvents":65,"numAffected":43,"numAtRisk":358},{"groupId":"EG002","numEvents":143,"numAffected":89,"numAtRisk":714}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":110,"numAffected":73,"numAtRisk":356},{"groupId":"EG001","numEvents":87,"numAffected":71,"numAtRisk":358},{"groupId":"EG002","numEvents":197,"numAffected":144,"numAtRisk":714}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":24,"numAtRisk":356},{"groupId":"EG001","numEvents":41,"numAffected":23,"numAtRisk":358},{"groupId":"EG002","numEvents":72,"numAffected":47,"numAtRisk":714}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":19,"numAtRisk":356},{"groupId":"EG001","numEvents":26,"numAffected":22,"numAtRisk":358},{"groupId":"EG002","numEvents":52,"numAffected":41,"numAtRisk":714}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":95,"numAffected":49,"numAtRisk":356},{"groupId":"EG001","numEvents":53,"numAffected":39,"numAtRisk":358},{"groupId":"EG002","numEvents":148,"numAffected":88,"numAtRisk":714}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":44,"numAtRisk":356},{"groupId":"EG001","numEvents":59,"numAffected":37,"numAtRisk":358},{"groupId":"EG002","numEvents":153,"numAffected":81,"numAtRisk":714}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":29,"numAtRisk":356},{"groupId":"EG001","numEvents":48,"numAffected":32,"numAtRisk":358},{"groupId":"EG002","numEvents":94,"numAffected":61,"numAtRisk":714}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":16,"numAtRisk":356},{"groupId":"EG001","numEvents":33,"numAffected":21,"numAtRisk":358},{"groupId":"EG002","numEvents":61,"numAffected":37,"numAtRisk":714}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":23,"numAtRisk":356},{"groupId":"EG001","numEvents":38,"numAffected":19,"numAtRisk":358},{"groupId":"EG002","numEvents":69,"numAffected":42,"numAtRisk":714}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":36,"numAtRisk":356},{"groupId":"EG001","numEvents":40,"numAffected":29,"numAtRisk":358},{"groupId":"EG002","numEvents":83,"numAffected":65,"numAtRisk":714}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":48,"numAtRisk":356},{"groupId":"EG001","numEvents":65,"numAffected":46,"numAtRisk":358},{"groupId":"EG002","numEvents":141,"numAffected":94,"numAtRisk":714}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":40,"numAtRisk":356},{"groupId":"EG001","numEvents":71,"numAffected":43,"numAtRisk":358},{"groupId":"EG002","numEvents":153,"numAffected":83,"numAtRisk":714}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":25,"numAtRisk":356},{"groupId":"EG001","numEvents":47,"numAffected":23,"numAtRisk":358},{"groupId":"EG002","numEvents":105,"numAffected":48,"numAtRisk":714}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":131,"numAffected":54,"numAtRisk":356},{"groupId":"EG001","numEvents":109,"numAffected":49,"numAtRisk":358},{"groupId":"EG002","numEvents":240,"numAffected":103,"numAtRisk":714}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":16,"numAtRisk":356},{"groupId":"EG001","numEvents":29,"numAffected":23,"numAtRisk":358},{"groupId":"EG002","numEvents":52,"numAffected":39,"numAtRisk":714}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":30,"numAtRisk":356},{"groupId":"EG001","numEvents":45,"numAffected":37,"numAtRisk":358},{"groupId":"EG002","numEvents":80,"numAffected":67,"numAtRisk":714}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":67,"numAffected":53,"numAtRisk":356},{"groupId":"EG001","numEvents":86,"numAffected":65,"numAtRisk":358},{"groupId":"EG002","numEvents":153,"numAffected":118,"numAtRisk":714}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":64,"numAffected":40,"numAtRisk":356},{"groupId":"EG001","numEvents":36,"numAffected":31,"numAtRisk":358},{"groupId":"EG002","numEvents":100,"numAffected":71,"numAtRisk":714}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":34,"numAtRisk":356},{"groupId":"EG001","numEvents":70,"numAffected":46,"numAtRisk":358},{"groupId":"EG002","numEvents":115,"numAffected":80,"numAtRisk":714}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":23,"numAtRisk":356},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":358},{"groupId":"EG002","numEvents":56,"numAffected":42,"numAtRisk":714}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":28,"numAtRisk":356},{"groupId":"EG001","numEvents":76,"numAffected":34,"numAtRisk":358},{"groupId":"EG002","numEvents":126,"numAffected":62,"numAtRisk":714}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":41,"numAtRisk":356},{"groupId":"EG001","numEvents":58,"numAffected":47,"numAtRisk":358},{"groupId":"EG002","numEvents":111,"numAffected":88,"numAtRisk":714}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":32,"numAtRisk":356},{"groupId":"EG001","numEvents":41,"numAffected":35,"numAtRisk":358},{"groupId":"EG002","numEvents":79,"numAffected":67,"numAtRisk":714}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":40,"numAtRisk":356},{"groupId":"EG001","numEvents":48,"numAffected":32,"numAtRisk":358},{"groupId":"EG002","numEvents":99,"numAffected":72,"numAtRisk":714}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":216,"numAffected":166,"numAtRisk":356},{"groupId":"EG001","numEvents":232,"numAffected":165,"numAtRisk":358},{"groupId":"EG002","numEvents":448,"numAffected":331,"numAtRisk":714}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":356},{"groupId":"EG001","numEvents":29,"numAffected":21,"numAtRisk":358},{"groupId":"EG002","numEvents":39,"numAffected":30,"numAtRisk":714}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":83,"numAffected":60,"numAtRisk":356},{"groupId":"EG001","numEvents":110,"numAffected":62,"numAtRisk":358},{"groupId":"EG002","numEvents":193,"numAffected":122,"numAtRisk":714}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":196,"numAffected":102,"numAtRisk":356},{"groupId":"EG001","numEvents":200,"numAffected":106,"numAtRisk":358},{"groupId":"EG002","numEvents":396,"numAffected":208,"numAtRisk":714}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-03-28","uploadDate":"2018-05-07T09:08","filename":"SAP_000.pdf","size":2178684},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-06-10","uploadDate":"2018-05-07T09:21","filename":"Prot_001.pdf","size":2725092}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Hong Kong","Slovakia"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}